United Kingdom · Question · Written question
UIN 3692
Alzheimer's Disease: Drugs
Introduced
2 September 2024
Last action
9 September 2024 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
9 September 2024
Summary
To ask the Secretary of State for Health and Social Care, with reference to the decision by the Medicines and Healthcare products Regulatory Agency on 22 August 2024 to licence lecanemab for patients with early stage Alzheimer's disease, what discussions
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
2 September 2024
Written question
To ask the Secretary of State for Health and Social Care, with reference to the decision by the Medicines and Healthcare products Regulatory Agency on 22 August 2024 to licence lecanemab for patients with early stage Alzheimer's disease, what discussions
Source: Commons
9 September 2024
Answer
Department officials have had a number of conversations with colleagues in NHS England about their plans to support the adoption of any licensed and National Institute for Health and Care Excellence (NICE) recommended treatment for Alzheimer’s disease.The...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2024-09-02/3692
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1726708
- uk · wq-1726708 · source updated 9 September 2024